Literature DB >> 17181376

An overview of the diagnosis and treatment of erectile dysfunction.

Sivaprakasam Sivalingam1, Hashim Hashim, Hartwig Schwaibold.   

Abstract

Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fueled the increase in treatment-seeking behaviour among men. Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting 'the couple' and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined 'step-ladder' escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17181376     DOI: 10.2165/00003495-200666180-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  76 in total

1.  Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.

Authors:  S A Ballard; C J Gingell; K Tang; L A Turner; M E Price; A M Naylor
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

2.  Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study.

Authors:  L A Levine; C R Estrada; A Morgentaler
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

3.  Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study.

Authors:  W W Dinsmore; C Gingell; G Hackett; P Kell; D Savage; R Oakes; G D Frentz
Journal:  BJU Int       Date:  1999-02       Impact factor: 5.588

4.  AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients.

Authors:  F Montorsi; P Rigatti; G Carmignani; C Corbu; B Campo; G Ordesi; G Breda; P Silvestre; B Giammusso; G Morgia; A Graziottin
Journal:  Eur Urol       Date:  2000-01       Impact factor: 20.096

5.  Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil.

Authors:  Edson Duarte Moreira; Carlos Fernando Lisboa Lbo; Agla Diament; Alfredo Nicolosi; Dale B Glasser
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

6.  Percutaneous embolization for erectile dysfunction due to venous leakage: prognostic factors for a good therapeutic result.

Authors:  M Fernández Arjona; R Oteros; M Zarca; J Díaz Fernández; I Cortes
Journal:  Eur Urol       Date:  2001-01       Impact factor: 20.096

7.  Apomorphine: an update of clinical trial results.

Authors:  J P Heaton
Journal:  Int J Impot Res       Date:  2000-10       Impact factor: 2.896

8.  Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.

Authors:  Hartmut Porst; Harin Padma-Nathan; François Giuliano; Greg Anglin; Lucio Varanese; Raymond Rosen
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

9.  American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update.

Authors:  Steven M Petak; Howard R Nankin; Richard F Spark; Ronald S Swerdloff; Luis J Rodriguez-Rigau
Journal:  Endocr Pract       Date:  2002 Nov-Dec       Impact factor: 3.443

10.  Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone.

Authors:  Brian D Rosenthal; Noah R May; Michael J Metro; Richard C Harkaway; Phillip C Ginsberg
Journal:  Urology       Date:  2006-03       Impact factor: 2.649

View more
  3 in total

Review 1.  Avanafil: a review of its use in patients with erectile dysfunction.

Authors:  Mark Sanford
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

Review 2.  What is the current role of intracavernosal injection in management of erectile dysfunction?

Authors:  A I El-Sakka
Journal:  Int J Impot Res       Date:  2016-04-14       Impact factor: 2.896

3.  The relevance of the procedures related to the physiotherapy in the interventions in patients with prostate cancer: short review with practice approach.

Authors:  Mario Bernardo-Filho; Mauro Luis Barbosa Júnior; Danúbia da Cunha Sá-Caputo; Eliane de Oliveira Guedes de Aguiar; Rafaelle Pacheco Carvalho de Lima; Sebastião David Santos-Filho; Severo de Paoli; Giuseppe Antonio Presta; Milena de Oliveira Bravo Monteiro; Angela Tavares
Journal:  Int J Biomed Sci       Date:  2014-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.